Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
País de afiliação
Intervalo de ano de publicação
1.
Vaccine ; 40(45): 6489-6498, 2022 10 26.
Artigo em Inglês | MEDLINE | ID: mdl-36195474

RESUMO

The rapid spread of COVID-19 on all continents and the mortality induced by SARS-CoV-2 virus, the cause of the pandemic coronavirus disease 2019 (COVID-19) has motivated an unprecedented effort for vaccine development. Inactivated viruses as well as vaccines focused on the partial or total sequence of the Spike protein using different novel platforms such us RNA, DNA, proteins, and non-replicating viral vectors have been developed. The high global need for vaccines, now and in the future, and the emergence of new variants of concern still requires development of accessible vaccines that can be adapted according to the most prevalent variants in the respective regions. Here, we describe the immunogenic properties of a group of theoretically predicted RBD peptides to be used as the first step towards the development of an effective, safe and low-cost epitope-focused vaccine. One of the tested peptides named P5, proved to be safe and immunogenic. Subcutaneous administration of the peptide, formulated with alumina, induced high levels of specific IgG antibodies in mice and hamsters, as well as an increase of IFN-γ expression by CD8+ T cells in C57 and BALB/c mice upon in vitro stimulation with P5. Neutralizing titers of anti-P5 antibodies, however, were disappointingly low, a deficiency that we will attempt to resolve by the inclusion of additional immunogenic epitopes to P5. The safety and immunogenicity data reported in this study support the use of this peptide as a starting point for the design of an epitope restricted vaccine.


Assuntos
COVID-19 , Vacinas Virais , Cricetinae , Humanos , Camundongos , Animais , SARS-CoV-2 , Epitopos , Glicoproteína da Espícula de Coronavírus/genética , Vacinas contra COVID-19 , COVID-19/prevenção & controle , Anticorpos Antivirais , Imunoglobulina G , Peptídeos , RNA , Óxido de Alumínio , Anticorpos Neutralizantes
2.
J Sep Sci ; 41(9): 2012-2019, 2018 May.
Artigo em Inglês | MEDLINE | ID: mdl-29377562

RESUMO

The application of layered double hydroxide-Al2 O3 -polymer mixed-matrix disks for solid-phase extraction is reported for the first time. Al2 O3 is embedded in a polymer matrix followed by an in situ metal-exchange process to obtain a layered double hydroxide-Al2 O3 -polymer mixed-matrix disk with excellent flow-through properties. The extraction performance of the prepared disks is evaluated as a proof of concept for the automated extraction using sequential injection analysis of organic acids (p-hydroxybenzoic acid, 3,4-dihydroxybenzoic acid, gallic acid) following an anion-exchange mechanism. After the solid-phase extraction, phenolic acids were quantified by reversed-phase high-performance liquid chromatography with diode-array detection using a core-shell silica-C18 stationary phase and isocratic elution (acetonitrile/0.5% acetic acid in pure water, 5:95, v/v). High sensitivity and reproducibility were obtained with limits of detection in the range of 0.12-0.25 µg/L (sample volume, 4 mL), and relative standard deviations between 2.9 and 3.4% (10 µg/L, n = 6). Enrichment factors of 34-39 were obtained. Layered double hydroxide-Al2 O3 -polymer mixed-matrix disks had an average lifetime of 50 extractions. Analyte recoveries ranged from 93 to 96% for grape juice and nonalcoholic beer samples.


Assuntos
Óxido de Alumínio/química , Hidróxidos/química , Hidroxibenzoatos/química , Polímeros/química , Extração em Fase Sólida , Automação , Cerveja/análise , Cromatografia Líquida de Alta Pressão , Sucos de Frutas e Vegetais/análise , Limite de Detecção , Microscopia Eletrônica de Varredura , Reprodutibilidade dos Testes
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA